Endoceutics files paperwork for $75M IPO

Canada's Endoceutics has filed the paperwork on an IPO designed to raise $75 million. Researchers at the company have been developing therapies for endocrine-related disorders in postmenopausal women and aging men as well as a hormone therapy for preventing breast cancer. Endoceutics has plans to launch three late-stage trials in the next year. The money will be used to advance two of its therapies to planned NDAs in 2008 and 2009. Analysts noted that the company reported only two full time workers on the payroll, with two more on contract. 

- read the Wall Street 24/7 report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.